首页> 外文期刊>Bone marrow transplantation >Reduced leukemia relapse through cytomegalovirus reactivation in killer cell immunoglobulin-like receptor-ligand-mismatched cord blood transplantation
【24h】

Reduced leukemia relapse through cytomegalovirus reactivation in killer cell immunoglobulin-like receptor-ligand-mismatched cord blood transplantation

机译:通过尖端血管病毒再激活减少白血病复发,在杀手细胞免疫球蛋白样受体 - 配体 - 错配脐带血移植中

获取原文
获取原文并翻译 | 示例
           

摘要

Cytomegalovirus (CMV) reactivation in cord blood transplantation (CBT) may result in the proliferation and maturation of natural killer (NK) cells. Similarly, a mismatch of the killer cell immunoglobulin-like receptor (KIR)-ligand induces NK cell activation. Therefore, if CMV reactivation occurs in the presence of KIR-ligand mismatch, it might improve CBT outcomes. We assessed the difference in the effect of CMV reactivation in the presence of KIR-ligand mismatch on disease relapse in the graft-versus-host direction. A total of 2840 patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, and chronic myeloid leukemia were analyzed. Among those with a HLA-Bw4/A3/A11 (KIR3DL-ligand) mismatch, CMV reactivation up to 100 days following CBT had a favorable impact on relapse (18.9% vs. 32.9%, P = 0.0149). However, this effect was not observed in cases without the KIR3DL-ligand mismatch or in those with or without a HLA-C1/C2 (KIR2DL-ligand) mismatch. The multivariate analysis suggested that CMV reactivation had a favorable effect on relapse only in cases with a KIR3DL-ligand mismatch (hazard ratio 0.54, P = 0.032). Moreover, the interaction effect between CMV reactivation and KIR3DL-ligand mismatch on relapse was significant (P = 0.039). Thus, our study reveals the association between KIR-ligand mismatches and CMV reactivation, which will enhance CBT outcomes.
机译:脐带血移植(CBT)中的巨细胞病毒(CMV)可重新激活可能导致天然杀伤剂(NK)细胞的增殖和成熟。类似地,杀手细胞免疫球蛋白样受体(KIR)--lig配体的不匹配诱导NK细胞活化。因此,如果在Kir-LigAnd不匹配存在下发生CMV再激活,则它可能会改善CBT结果。我们评估了CMV再活化在基于移植物与主机方向上的疾病复发存在下存在的CMV再活化的差异。分析了共有2840例急性髓性白血病,急性淋巴细胞白血病,骨髓增强性综合征和慢性髓性白血病患者。在HLA-BW4 / A3 / A11(Kir3D1-配体)中的那些中,CBT在CBT后100天的CMV再激活对复发有良好的影响(18.9%vs.32.9%,P = 0.0149)。然而,在没有KIR3DL-配体不匹配的情况下或在有或没有HLA-C1 / C2(KIR2DL-配体)失配的情况下未观察到这种效果。多变量分析表明,在Kir3dl-ligand失配(危险比0.54,p = 0.032)的情况下,CMV再激活对复发有利的影响。此外,CMV再激活与kir3dl-ligand失配对复发的相互作用效应显着(p = 0.039)。因此,我们的研究揭示了Kir-Ligand失配和CMV再活化之间的关联,这将增强CBT结果。

著录项

  • 来源
    《Bone marrow transplantation》 |2021年第6期|共12页
  • 作者单位

    Tohoku Univ Grad Sch Med Dept Hematol &

    Rheumatol Sendai Miyagi Japan;

    Kyoto Univ Grad Sch Med Dept Hematol &

    Oncol Kyoto Japan;

    Jichi Med Univ Sch Med Dept Pediat Shimotsuke Tochigi Japan;

    Federat Natl Publ Serv Personnel Mutual Aid Assoc Dept Hematol Tokyo Japan;

    Kanagawa Canc Ctr Dept Hematol Yokohama Kanagawa Japan;

    Univ Tokyo Inst Med Sci Div Mol Therapy Adv Clin Res Ctr Tokyo Japan;

    Tokai Univ Sch Med Dept Hematol Oncol Isehara Kanagawa Japan;

    Komagome Hosp Tokyo Metropolitan Canc &

    Infect Dis Ctr Hematol Div Tokyo Japan;

    Japanese Red Cross Nagoya First Hosp Dept Hematol Nagoya Aichi Japan;

    Natl Hosp Org Sendai Med Ctr Dept Hematol Sendai Miyagi Japan;

    Sapporo Hokuyu Hosp Dept Hematol Sapporo Hokkaido Japan;

    Kitakyushu Municipal Med Ctr Kitakyushu City Hosp Org Dept Hematol Kitakyushu Fukuoka Japan;

    Japanese Red Cross Kinki Block Blood Ctr Preparat Dept Ibaraki Japan;

    Jichi Med Univ Div Hematol Shimotsuke Tochigi Japan;

    Hiroshima Univ Res Inst Radiat Biol &

    Med Dept Hematol &

    Oncol Hiroshima Japan;

    Japanese Data Ctr Hematopoiet Cell Transplantat Nagoya Aichi Japan;

    Jichi Med Univ Div Hematol Saitama Med Ctr Saitama Japan;

    Univ Ryukyus Div Endocrinol Diabet &

    Metab Dept Internal Med 2 Hematol Rheumatol Grad Sch Med;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 治疗学;
  • 关键词

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号